IPO UPDATE: NeuroDerm's CEO felt well-received, but FibroGen soared
This article was originally published in Scrip
Executive Summary
The drug developers NeuroDerm and FibroGen launched initial public offerings on 14 November with two very different results, but even though NeuroDerm's IPO priced below a preliminary range and the stock fell in its first day of trading, CEO Oded Lieberman told Scrip that the Israeli company's Parkinson's disease story "resonated well" with investors.